The Pharma Data

DECEMBER 7, 2020

7, 2020 — Scientists say they may be getting closer to creating a universal flu vaccine. In an early-stage clinical trial with 65 volunteers in the United States, an experimental vaccine triggered strong immune responses to a wide range of flu virus strains and subtypes. MONDAY, Dec.

Scientist 52

Scientist Vaccination Vaccine Immune Response 52

STAT News

OCTOBER 19, 2022

1 subvariant of Omicron generated a strong immune response against that variant, with antibody levels staying high for at least three months , Reuters notes. Omicron-tailored Have a wonderful day, and please do stay in touch. … Moderna disclosed that its Covid-19 vaccine booster targeting the BA.1

Immune Response 98

Immune Response Scientist Vaccination Vaccine 98

The Pharma Data

SEPTEMBER 14, 2020

Illustration of antibodies attacking the coronavirus. A new antibody treatment is to be trialled on Covid-19 patients in UK hospitals. Monoclonal antibodies, which are potent, laboratory-made antibodies, will be given to about 2,000 people to see if they are effective against coronavirus. What are monoclonal antibodies?

Antibody 52

Antibody Trials Immune Response Vaccination 52

pharmaphorum

FEBRUARY 25, 2021

A nasal delivery method will also produce an immune response at the point where the virus enters the body. The company announced a phase 1 trial is beginning of its nasal spray vaccine just as scientists in the UK said they are considering a similar approach.

Vaccination 110

Vaccination Vaccine Immune Response Trials 110

Drug Discovery World

APRIL 11, 2024

We have noted that cancer patients can develop powerful anti-tumour immune responses that can result in complete cure of the disease and we call these patients ‘elite responders’. By understanding what triggers the adaptive immune response in “elite responders” we have identified new targets and therapeutic antibodies.

Research 59

Research Immune Response Antibody Medicine 59

Scienmag

AUGUST 21, 2020

While antibodies may fade fast, T cells appear to be long-lived and might confer lasting immunity.

Immune Response 40

Immune Response Antibody Scientist Allergies 40

pharmaphorum

JANUARY 15, 2021

In order to make the best use of scarce vaccine resources the UK has opted to extend the time between doses to up to 12 weeks, a strategy that has been criticised by some scientists who are fearful that it could cause vaccine-tolerant strains of the virus to emerge.

Vaccination 118

Vaccination Vaccine Immune Response Antibody 118

pharmaphorum

JUNE 30, 2021

Just a few months after starting clinical trials of its nasal spray vaccine for COVID-19, US biotech Altimmune is abandoning the project, saying that it generated weaker than expected immune responses in a phase 1 trial. . We believe that prior immunity in humans may be important for a robust immune response to intranasal dosing.”

Vaccination 98

Vaccination Vaccine Trials Immune Response 98

The Pharma Data

DECEMBER 11, 2020

The test has been designed to quantitatively measure of immunoglobulin G (IgG) antibodies to aid clinicians in identifying patients with an immune Covid-19 response pre- and post-vaccination. As we follow individuals over the course of a year, we are repeatedly testing them for both virus and antibodies.”.

Antibody 52

Antibody Vaccination Vaccine Containment 52

World of DTC Marketing

APRIL 11, 2021

A second study by scientists in the United States, published alongside the Imperial-led one in the journal Nature, estimated that lockdowns in China, South Korea, Italy, Iran, France and the United States had prevented or delayed around 530 million COVID-19 cases.

Vaccination 303

Vaccination Vaccine Clinical Trials Clinical Trials 303

pharmaphorum

MAY 19, 2022

It codes for an antigen called eOD-GT8 60mer and, in the study, stimulated a targeted B-cell immune response in 97% of vaccine recipients. One candidate – mRNA-1644 – has already shown its potential in an earlier phase 1 trial (IAVI G001) run in the US. HVAD #HVAD2022 pic.twitter.com/KLrVRXtEAv.

Vaccination 145

Vaccination Vaccine Trials Immune Response 145

Sciensano

JULY 5, 2023

Vaccin COVID-19 Event type: symposium Audience: general public health professionals journalist PhD students policy makers scientists Description: Sciensano is pleased to invite you to its BelCoVac symposium, which will focus on studies on the COVID vaccine in Belgium.

Vaccination 52

Vaccination Vaccine Immune Response Antibody 52

Drug Discovery World

JANUARY 12, 2024

The top stories: Excitement over new antibiotics that can kill drug-resistant bacteria A novel antibiotic class targeting a major global pathogen and threat to human health has been discovered by scientists from Roche and Harvard University (Cambridge, MA, US).

Drugs 52

Drugs Immune Response Allergies Bacteria 52

XTalks

JANUARY 11, 2023

It also seems to be very adept at evading the immune response owing to a plethora of mutations that makes it immune evasive. “It The new subvariant has also been dubbed “Kraken” by some scientists. on the horizon as scientists say the virus appears to be rapidly evolving , mutating faster than most viruses.

Scientist 98

Scientist Vaccination Vaccine Genetics 98

The Pharma Data

DECEMBER 29, 2020

As in earlier outpatient trial, immune status when patients entered the trial was a strong predictor of viral load and clinical outcomes. First antibody therapy to demonstrate anti-viral effect in patients hospitalized with COVID-19. Regeneron Pharmaceuticals, Inc. futility analysis). The results passed the futility analysis (p<0.3

Antibody 52

Antibody Trials Production Clinical Trials 52

Drug Discovery World

FEBRUARY 28, 2024

Scientists have used CRISPR gene editing to target and rapidly destroy glioblastoma cells in an approach that could apply to other highly mutated cancers. A Phase I clinical trial, sponsored and managed by Cancer Research UK’s Centre for Drug Development, tested whether a type of antibody called IgE could be used to treat cancer.

Development 64

Development Research Drugs Antibody 64

pharmaphorum

DECEMBER 11, 2020

Interim results from a phase 1/2 clinical trial show the immune response from Sanofi/GSK’s vaccine produced a lower immune response in older adults. While antibody levels were comparable to those seen in recovering COVID-19 patients in adults aged 18-49, the response was lower in older adults.

Immune Response 67

Immune Response Trials Vaccination Vaccine 67

Find Me Cure

APRIL 23, 2020

The far more boring truth is that scientists are not magicians or prophets and estimations cannot always be precise. Firstly, even though scientists are busy developing a vaccine, one is not expected earlier than 2021. Thus, herd immunity wouldn’t work in this scenario. Myth 3: Healthy young people don’t get sick.

Immune Response 117

Immune Response Antibody Scientist Development 117

The Pharma Data

MARCH 13, 2022

People who gained immunity – either through vaccination or exposure – against the original strain of SARS-CoV-2, the virus that causes COVID-19, also are likely to have some protection against the pathogen’s omicron variant. The samples were stored after the researchers measured the T cell response.

Immune Response 52

Immune Response Protein Medicine Genetics 52

pharmaphorum

FEBRUARY 18, 2021

Researchers from the University of Texas Medical Branch based their findings on lab tests using SARS-CoV-2 coronaviruses that were genetically engineered to have the same mutations as those in the strain that is causing scientists so much concern.

Immune Response 52

Immune Response Genetic Engineering Vaccination Vaccine 52

Drug Discovery World

JULY 26, 2022

The talk will cover the technology behind the vaccine and the mechanisms of antibody and T cell immune responses triggered by the Covid-19 mRNA vaccine. . The lecture is one of a series of named lectures, organised by the LMB and given by eminent scientists from around the world. .

Vaccination 52

Vaccination Vaccine Immune Response Antibody 52

Drug Discovery World

OCTOBER 13, 2023

The scientists say the tool can help inform the development of vaccines and therapies for SARS-CoV-2 and other rapidly mutating viruses. The scientists first developed the generative model EVE (evolutionary model of variant effect) to predict gene mutations that cause human diseases.

Vaccination 105

Vaccination Vaccine Immune Response Scientist 105

XTalks

JANUARY 20, 2021

Through laboratory and clinical studies, the scientists discovered that blockade of histamine could help alleviate IBS symptoms. While diseases like celiac are associated with inappropriate activation of the immune system triggered by food antigens, this is not the case in IBS. Mouse and Human Studies.

Immune Response 52

Immune Response Research Allergies Protein 52

The Pharma Data

DECEMBER 17, 2020

NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. TARRYTOWN, N.Y. , 17, 2020 /PRNewswire/ — Regeneron Pharmaceuticals, Inc.

Antibody 52

Antibody Medicine Production Trials 52

XTalks

DECEMBER 12, 2023

Human plasma, the clear, liquid portion of blood, is composed of water, electrolytes, nutrients and crucial proteins such as antibodies, clotting factors and albumin. The team includes outstanding scientists and researchers around the world who look to push the boundaries of what’s possible to discover the next breakthroughs.

Medicine 111

Medicine Recombinant Antibody Protein Antibody 111

The Pharma Data

AUGUST 15, 2021

Even as several safe and effective COVID-19 vaccines are being administered to people worldwide, scientists are still hard at work developing different vaccine strategies that could provide even stronger or longer-lasting immunity against SARS-CoV-2 and its variants.

Protein 52

Protein Vaccination Vaccine Antibody 52

The Pharma Data

NOVEMBER 10, 2021

Next generation vaccines for COVID-19 should aim to induce an immune response against ‘replication proteins’, essential for the very earliest stages of the viral cycle, concludes new research carried out by UCL scientists. ” Why might some individuals be able to clear an infection better than others?

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

pharmaphorum

NOVEMBER 25, 2022

Scientists in the US say they have developed an mRNA-based vaccine that encompasses all 20 known subtypes of influenza that could form the basis of a future universal jab. The goals of the programme are also similar to those in COVID vaccine development. That included viruses that were significantly different from those included in the shot.

Vaccination 105

Vaccination Vaccine Research Immune Response 105

The Pharma Data

OCTOBER 28, 2020

NASDAQ: REGN) today announced positive, prospective results from an ongoing Phase 2/3 seamless trial in the COVID-19 outpatient setting showing its investigational antibody cocktail, REGN-COV2, met the primary and key secondary endpoints. Regeneron Pharmaceuticals, Inc. Yancopoulos , M.D., President and Chief Scientific Officer of Regeneron.

Antibody 40

Antibody Trials Production Clinical Trials 40

The Pharma Data

MARCH 8, 2022

In this way, the viral RNA escapes early recognition by the central antiviral immune-receptor RIG-I. This receptor normally induces a so called innate immune response in which antiviral active proteins, cell signals and messenger substances – such as type I interferon (IFN) – are generated.

Immune Response 52

Immune Response RNA Protein Genetics 52

pharmaphorum

SEPTEMBER 29, 2020

Once inside the cell, the DNA plasmids instruct the cell to produce the targeted antigen, triggering an immune response against the antigen. So far however Inovio has reported relatively sparse data with its vaccine, with limited results from a phase 1 human trial in June and following that with non-human primate data in July.

Vaccination 52

Vaccination Vaccine Trials DNA 52

The Pharma Data

AUGUST 9, 2021

Research by Lancaster University scientists to create a COVID-19 vaccine which can be administered through the nose has taken a significant step forward. The scientists engineered NDV to produce the spike proteins of the SARS-CoV-2 virus which causes COVID-19, tricking the body into mounting an immune response against SARS-CoV-2.

Vaccination 52

Vaccination Vaccine Immune Response Scientist 52

The Pharma Data

OCTOBER 18, 2021

Northwestern Medicine scientists have shown for the first time that coronavirus vaccines and prior coronavirus infections can provide broad immunity against other, similar coronaviruses. “A reason we don’t have an effective HIV vaccine is because it’s hard to develop cross-reactive antibodies,” Penaloza-MacMaster said.

Vaccination 40

Vaccination Vaccine Immune Response Antibody 40

pharmaphorum

SEPTEMBER 8, 2022

g) dose of Novavax’ Matrix-M adjuvant, used to boost the immune response to the R21 antigen. The scientists behind the R21/Matrix-M also say that it is more simple to produce, which could make rolling it out at scale across areas where malaria is endemic easier – assuming funding to do so is made available. .

Vaccination 71

Vaccination Vaccine Immune Response Antibody 71

The Pharma Data

SEPTEMBER 30, 2021

An expert review by a world group of scientists, including some at the WHO and FDA, concludes that, even for the delta variant, vaccine efficacy against severe COVID is so high that booster doses for the overall population aren’t appropriate at this stage within the pandemic. Considerations in boosting COVID-19 vaccine immune responses.

Vaccination 52

Vaccination Vaccine Antibody Immune Response 52

The Pharma Data

JANUARY 3, 2021

Furthermore, nasal anti-CD3 dampens cytotoxic CD8 T cell responses that are known to cause lung damage in COVID-19 patients.”. Dr Thais Moreira, the lead scientist and coordinator of the clinical trial, stated: “We are delighted to receive positive feedback from patients treated in the clinical trial. . NEW YORK and LONDON, Jan.

Life Science 40

Life Science Clinical Trials Clinical Trials Antibody 40

Delveinsight

FEBRUARY 11, 2021

Verily collaborates with Janssen to launch COVID-19 immune response study. Verily is partnering with Johnson & Johnson’s Janssen division to witness the body’s earliest immune responses to a coronavirus infection, with people participating in the research from within their homes. .

Gene Therapy 52

Gene Therapy Gene Immune Response In-Vivo 52